Abstract

Radiolabeled PEGylated peptide radiotracer for detection of integrin alpha-v beta-6 in vitro and in vivo

Full Description

Researchers at the University of California, Davis have developed a method for the convenient synthesis and improved in vivo behavior of a probe for targeted in vivo and in vitro detection of the integrin alpha-v beta-6 (α_vß₆), a cell surface receptor linked to certain cancers. Using this method, UC Davis researchers have identified pancreatic cancer as a novel target for imaging α_vß₆-expression in vivo and successfully imaged a mouse model by PET. Tumors not detected by standard imaging probes were clearly visualized by these peptide conjugates. Additionally, the peptide conjugates developed by this method are fully compatible with standard peptide and radiolabeling chemistries, thus making the approach widely employable.

Positron emission tomography (PET) transaxial images of pancreatic cancer model in a mouse. The alpha-v beta-6 targeting peptide conjugate clearly revealed the tumor.

Applications

Positron emission tomography (PET) imaging of α_vß_6--expression in tumors for detection of often-overlooked cancers (e.g., pancreatic cancer).

Features/Benefits

• May serve as a diagnostic and prognostic indicator of disease in a noninvasive manner
• May lead to the development of other imaging probes and targets
  

PATENT STATUS

• Patent Pending

INVENTORS

• Hausner, Sven H.
• Marshall, John F.
• Sutcliffe, Julie L.

Other Information

Contact

Nancy E. Rashid/ nerashid@ucdavis.edu / tel: 530-754-8621. Please reference Tech ID #19162.

Request Additional Information